In silico analysis of HLA associations with drug-induced liver injury: Use of a HLA-genotyped DNA archive from healthy volunteers

Genome Medicine

Volumn 4, Issue 6, 2012, Pages

  Alfirevic, Ana ^a   Gonzalez Galarza, Faviel ^a   Bell, Catherine ^a   Martinsson, Klara ^a,b   Platt, Vivien ^a   Bretland, Giovanna ^a   Evely, Jane ^a   Lichtenfels, Maike ^a   Cederbrant, Karin ^b   French, Neil ^a   Naisbitt, Dean ^a   Park, B Kevin ^a   Jones, Andrew R ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAMAZEPINE; CLOMETACIN; DICLOFENAC; DNA; FLUCLOXACILLIN; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; ISONIAZID; LAMOTRIGINE; LAPATINIB; LUMIRACOXIB; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; TICLOPIDINE; XIMELAGATRAN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BIOINFORMATICS; CAUCASIAN; CHINESE; DRUG HYPERSENSITIVITY; ETHNICITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HLA SYSTEM; HOMOZYGOTE; HUMAN; HUMAN CELL; INDIAN; JAPANESE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS;

EID: 84862631961     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm350     Document Type: Article

References (48)

1. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007, 47:513-539. 10.1146/annurev.pharmtox.47.120505.105150, 16879083.
2. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. Metabolic activation in drug allergies. Toxicology 2001, 158:11-23. 10.1016/S0300-483X(00)00397-8, 11164988.
3. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002, 2:301-305. 10.1097/00130832-200208000-00003, 12130944.
4. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486. 10.1038/428486a, 15057820.
5. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009, 29:400-411. 10.1055/s-0029-1240009, 19826974.
6. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819. 10.1038/ng.379, 19483685.
7. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010, 53:1049-1053. 10.1016/j.jhep.2010.05.033, 20800921.
8. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PS, Rahier J, Geubel AP. HLA association of amoxicillin-clavulanate - induced hepatitis. Gastroenterology 1999, 117:1181-1186. 10.1016/S0016-5085(99)70404-X, 10535882.
9. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, Shimizu S, Masumoto H, Okutani Y. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008, 8:29-33. 10.1038/sj.tpj.6500442, 17339877.
10. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005, 102:4134-4139. 10.1073/pnas.0409500102, 554812, 15743917.
11. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerstrom-Fermer ME, Dellsen A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, Billing-Clason SM, Cardon LR, March RE. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2007, 8:186-195.
12. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99-107. 10.1097/FPC.0b013e3282f3ef9c, 18192896.
13. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141:338-347. 10.1053/j.gastro.2011.04.001, 3129430, 21570397.
14. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732. 10.1016/S0140-6736(02)07873-X, 11888582.
15. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579. 10.1056/NEJMoa0706135, 18256392.
16. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS (London, England) 2005, 19:97-99.
17. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O'Connor GD, Chaila E, Alhusaini S, Shianna KV, Radtke RA, Heinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143. 10.1056/NEJMoa1013297, 3113609, 21428769.
18. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000, 47:717-720. 10.1136/gut.47.5.717, 1728095, 11034591.
19. Pariente EA, Hamoud A, Goldfain D, Latrive JP, Gislon J, Cassan P, Morin T, Staub JL, Ramain JP, Bertrand JL. Hepatitis caused by clometacin (Duperan). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?. Gastroenterologie Clinique Biologique 1989, 13:769-774.
20. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166:916-919. 10.1164/rccm.2108091, 12359646.
21. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010, 42:711-714. 10.1038/ng.632, 20639878.
22. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011, 29:667-673. 10.1200/JCO.2010.31.3197, 21245432.
23. Horton H, Weston SD, Hewitt CR. Allergy to antibiotics: T-cell recognition of amoxicillin is HLA-DR restricted and does not require antigen processing. Allergy 1998, 53:83-88.
24. de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, Ke X, Monsuur AJ, Whittaker P, Delgado M, Morrison J, Richardson A, Walsh EC, Gao X, Galver L, Hart J, Hafler DA, Pericak-Vance M, Todd JA, Daly MJ, Trowsdale J, Wijmenga C, Vyse TJ, Beck S, Murray SS, Carrington M, Gregory S, Deloukas P, Rioux JD. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006, 38:1166-1172. 10.1038/ng1885, 2670196, 16998491.
25. Almeida CA, Martin AM, Nolan D, Lucas A, Cameron PU, James I, Phillips E, Mallal S. Cytokine profiling in abacavir hypersensitivity patients. Antivir Ther 2008, 13:281-288.
26. Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, James I, McCluskey J, Phillips E, Landay A, Mallal S. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS (London, England) 2007, 21:1233-1244.
27. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003, 63:732-741. 10.1124/mol.63.3.732, 12606784.
28. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, Berry N, Stachulski AV, Clarke SE, Pichler WJ, Pirmohamed M, Park BK, Naisbitt DJ. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006, 118:233-241. 10.1016/j.jaci.2006.03.005, 16815161.
29. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008, 28:822-832. 10.1016/j.immuni.2008.04.020, 18549801.
30. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 2006, 118:42-50. 10.1016/j.clim.2005.08.017, 16260183.
31. Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermuller J, Stadler PF, Hartung HP, Berthele A, Deisenhammer F, Wassmuth R, Hemmer B. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008, 83:219-227. 10.1016/j.ajhg.2008.07.006, 2495071, 18656179.
32. Royal Liverpool and Broadgreen University Hospital Clinical Research Facility. , http://www.liverpoolbrc.org/facilities/clinical_research_facility.aspx
33. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011, 39:D913-919. 10.1093/nar/gkq1128, 3013710, 21062830.
34. Allele Frequency Net Database. , http://www.allelefrequencies.net/
35. dbMHC. , http://www.ncbi.nlm.nih.gov/gv/mhc/
36. Schreuder GM, Hurley CK, Marsh SG, Lau M, Fernandez-Vina M, Noreen HJ, Setterholm M, Maiers M. The HLA Dictionary 2004: a summary of HLA-A, -B, -C, -DRB1/3/4/5 and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens 2005, 65:1-55. 10.1111/j.1399-0039.2005.00350.x, 15663741.
37. Lancaster AK, Single RM, Solberg OD, Nelson MP, Thomson G. PyPop update - a software pipeline for large-scale multilocus population genomics. Tissue Antigens 2007, 69(Suppl 1):192-197.
38. Sanchez-Mazas A, Djoulah S, Busson M, Le Monnier de Gouville I, Poirier JC, Dehay C, Charron D, Excoffier L, Schneider S, Langaney A, Dausset J, Hors J. A linkage disequilibrium map of the MHC region based on the analysis of 14 loci haplotypes in 50 French families. Eur J Hum Genet 2000, 8:33-41. 10.1038/sj.ejhg.5200391, 10713885.
39. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995, 12:921-927.
40. Zhao JH. Pedigree-drawing with R and graphviz. Bioinformatics 2006, 22:1013-1014. 10.1093/bioinformatics/btl058, 16488908.
41. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009, 61:1-13. 10.1007/s00251-008-0341-z, 3319061, 19002680.
42. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S. NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 2010, 6:9. 10.1186/1745-7580-6-9, 2994798, 21073747.
43. PHYLIP. , http://evolution.genetics.washington.edu/phylip.html
44. Molecular Evolutionary Genetics Analysis (MEGA). , http://www.megasoftware.net/
45. Ellson CD, Andrews S, Stephens LR, Hawkins PT. The PX domain: a new phosphoinositide-binding module. J Cell Sci 2002, 115:1099-1105.
46. Schultz H. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). Autoimmun Rev 2007, 6:223-227. 10.1016/j.autrev.2006.08.005, 17317612.
47. Hurley CK, Setterholm M, Lau M, Pollack MS, Noreen H, Howard A, Fernandez-Vina M, Kukuruga D, Muller CR, Venance M, Wade JA, Oudshoorn M, Raffoux C, Enczmann J, Wernet P, Maiers M. Hematopoietic stem cell donor registry strategies for assigning search determinants and matching relationships. Bone Marrow Transplant 2004, 33:443-450. 10.1038/sj.bmt.1704365, 14676778.
48. Lopes JA, Jorge S, Goncalves S, Resina C, Silva S, de Almeida E, Abreu F, Lourenco F, Martins C, Lacerda JF, do Carmo JA, Prata MM. Contemporary analysis of the influence of acute kidney injury (AKI) after myeloablative hematopoietic cell transplantation on long-term patient's survival. Bone Marrow Transplant 2008, 42:139-141. 10.1038/bmt.2008.97, 18425145.